Evidence map›Paper›PMID 33714983›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2021

NUTM1-rearranged colorectal sarcoma: a clinicopathologically and genetically distinctive malignant neoplasm with a poor prognosis.

Benjamin J Van Treeck, Judith Jebastin Thangaiah, Jorge Torres-Mora, Todd M Stevens, Christian Rothermundt, Matteo Fassan, Fotios Loupakis, Joachim Diebold, Jason L Hornick, Kevin C Halling and 1 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Detection of sarcoma fusions by a next-generation sequencing based-ligation-dependent multiplex RT-PCR assay.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022
    Article
  11. Review
  12. Review
  13. Current oncology (Toronto, Ont.) · 2021
    Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 3 countries.

Benjamin J Van TreeckDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Judith Jebastin ThangaiahDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Jorge Torres-MoraDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Todd M StevensDivision of Anatomic Pathology, University of Alabama at Birmingham, Birmingham, AL, USA.
Christian RothermundtDepartment of Oncology and Hematology, St. Gallen Cantonal Hospital, St. Gallen, Switzerland.
Matteo FassanDepartment of Medicine, Surgical Pathology Unit, University of Padua, Padua, Italy.ORCID 0000-0001-6515-5482
Fotios LoupakisUnit of Medical Oncology 1, Department of Oncology, Veneto Institute of Oncology IRCCS, Padua, Italy.
Joachim DieboldDepartment of Pathology, Cantonal Hospital, Lucerne, Switzerland.
Jason L HornickDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-6475-8345
Kevin C HallingDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Andrew L FolpeDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. Folpe.Andrew@Mayo.edu.
Mayo Clinic in Arizona · USBrigham and Women's Hospital · USIstituto Oncologico Veneto · ITKantonsspital St. Gallen · CHMayo Clinic · USUniversity of Alabama at Birmingham · USUniversity of Lucerne · CHUniversity of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

NUTM1 gene rearrangements were originally identified in NUT carcinoma. Recently, NUTM1 has been discovered to rearrange with a variety of gene partners in malignancies of diverse location and type. Only one NUTM1-rearranged tumor occurring in the colon has been reported. Herein we report five such tumors. The five tumors occurred in four females and one male, ranging from 38 to 67 years of age (median 51 years). The masses occurred in the colon (cecum, descending, sigmoid) and ileocecal valve region, measuring 2.5-20 cm in size (median 7 cm). Four patients had metastases at presentation (liver, n = 4; lymph nodes, n = 3). Histologically, the lesions arose in the submucosa, infiltrating into the mucosa and muscularis propria, and grew in fibrosarcoma-like fascicles and sheets of epithelioid or rhabdoid cells, with foci of hyalinized to vaguely osteoid-like matrix. The tumors were composed of relatively monomorphic, spindled to epithelioid cells with focal rhabdoid morphology, hyperchromatic nuclei, and small nucleoli. Mitotic activity was usually low (range 1-14/10 HPF; median 5/10 HPF); necrosis was present in two cases. Variable keratin expression and uniform nuclear NUT expression was present; KIT/DOG1 were negative and SMARCB1/SMARCA4 were retained. Next-generation sequencing identified MXD4-NUTM1 rearrangement in all cases (breakpoints: MXD4 exon 5, NUTM1 exons 2 or 3). Follow-up showed one of the four patients who presented with metastases to be dead of disease at 30 months; the other three patients were alive with metastatic disease. The final patient is disease-free, 5 months after diagnosis. NUTM1-rearranged colorectal sarcomas have characteristic morphologic, immunohistochemical, and molecular genetic features, suggesting that they represent a distinct entity within the family of NUTM1-rearranged neoplasia. A NUTM1-rearranged tumor should be considered for any difficult-to-classify submucosal spindle cell neoplasm of the gastrointestinal tract, in particular keratin-positive tumors showing an unusual combination of fibrosarcomatous, epithelioid to rhabdoid and hyalinized morphologies. Recognition of MXD4-NUTM1 rearranged sarcomas may be therapeutically important, even though best treatment is currently elusive/unknown.

Indexed as

AdultAgedBasic Helix-Loop-Helix ProteinsBiomarkers, TumorColorectal NeoplasmsFemaleGene RearrangementHumansMaleMiddle AgedNeoplasm ProteinsNuclear ProteinsOncogene FusionOncogene Proteins, FusionPrognosisRepressor ProteinsBasic Helix-Loop-Helix ProteinsBiomarkers, TumorMXD4 protein, humanNeoplasm ProteinsNuclear ProteinsNUTM1 protein, humanOncogene Proteins, FusionRepressor Proteins

Identifiers

PMID33714983
OpenAlexW3139209589

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.